What are the advantages of treating rare diseases with regenerative medicine? (part 2)

In this teaser from an upcoming #TalkingRegMed, Sven Kili, VP and Head of Cell & Gene Therapy Development, GlaxoSmithKline, explains why rare diseases are so amenable to being treated with regenerative medicine.

Watch part 1 here: https://youtu.be/zepb-hPzHFI

For more exclusive rare disease content, visit the RegMedNet focus on rare diseases: http://bit.ly/2ohdvyb

source